Ionis Pharmaceuticals, Inc. Common Stock (IONS) Stock Price
IONSStock
$42.94−41.23%52W
Market Cap$7.14B
P/E—
PEG Ratio27.33
Div yield—
Beta0.39
IONS Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-53.96%
Price vs S&P 500 (4W)-3.04%
PEG Ratio27.33
VGM Score36.56
IONS Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.88 | -$0.42 | +51.70%(+$0.45) | |
| Q1 2026 | -$0.78 | -$0.30 | +60.90%(+$0.47) | |
| Q4 2025 | -$1.22 | -$1.15 | +5.56%(+$0.07) | |
| Q3 2025 | -$1.05 | -$0.61 | +41.81%(+$0.44) | |
| Q2 2025 | $0.16 | $0.85 | +415.06%(+$0.68) |
IONS Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.12
4.15
4.06
4.03
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
IONSIonis Pharmaceuticals, Inc. Common Stock | D | D | C | 8.2x | -7.5% | 98.2% | — | $42.94 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Ionis Pharmaceuticals, Inc. Common Stock
Ionis Pharmaceuticals is a leader in antisense technology with a diverse clinical pipeline targeting cardiovascular, metabolic, neurological, and rare diseases. The company has established multiple marketed drugs through partnerships, including Spinraza (spinal muscular atrophy), Qalsody (ALS), and Tegsedi (ATTR amyloidosis), while achieving its first independent launches in 2025 with Tryngolza and Dawnzera. Ionis combines partnership-driven revenue streams with growing direct commercialization capabilities.